MariTime CV (Recruiting)

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants Living with Overweight or Obesity and Atherosclerotic Cardiovascular Disease